Back to Search Start Over

Defining Target Engagement Required for Efficacy In Vivo at the Retinoic Acid Receptor-Related Orphan Receptor C2 (RORγt).

Authors :
Lugar CW
Clarke CA
Morphy R
Rudyk H
Sapmaz S
Stites RE
Vaught GM
Furness K
Broughton HB
Durst GL
Clawson DK
Stout SL
Guo SY
Durbin JD
Stayrook KR
Edmondson DD
Kikly K
New NE
Bina HA
Chambers MG
Shetler P
Chang WY
Chang VC
Barr R
Gough WH
Steele JP
Getman B
Patel N
Mathes BM
Richardson TI
Source :
Journal of medicinal chemistry [J Med Chem] 2021 May 13; Vol. 64 (9), pp. 5470-5484. Date of Electronic Publication: 2021 Apr 14.
Publication Year :
2021

Abstract

The Th17 pathway has been implicated in autoimmune diseases. The retinoic acid receptor-related orphan receptor C2 (RORγt) is a master regulator of Th17 cells and controls the expression of IL-17A. RORγt is expressed primarily in IL-17A-producing lymphoid cells. Here we describe a virtual screen of the ligand-binding pocket and subsequent screen in a binding assay that identified the 1-benzyl-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3- c ]pyran]-2'-carboxamide scaffold as a starting point for optimization of binding affinity and functional activity guided by structure-based design. Compound 12 demonstrated activity in a mouse PK/PD model and efficacy in an inflammatory arthritis mouse model that were used to define the level and duration of target engagement required for efficacy in vivo . Further optimization to improve ADME and physicochemical properties with guidance from simulations and modeling provided compound 22 , which is projected to achieve the level and duration of target engagement required for efficacy in the clinic.

Details

Language :
English
ISSN :
1520-4804
Volume :
64
Issue :
9
Database :
MEDLINE
Journal :
Journal of medicinal chemistry
Publication Type :
Academic Journal
Accession number :
33852312
Full Text :
https://doi.org/10.1021/acs.jmedchem.0c01918